Onal, CemSedef, Ali MuratKose, FatihOymak, EzgiGuler, Ozan CemSumbul, Ahmet TanerAksoy, SercanYildirim, Berna AkkusBesen, Ali AyberkMuallaoglu, SadikMertsoylu, HuseyinOzyigit, Gokhan2020-11-022020-11-0220191479-6694http://hdl.handle.net/11727/4993Currently, there are no predictive markers of response to abiraterone. We calculated neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) at baseline and at 4 and 12 weeks after initiation of abiraterone, and we evaluated prostate-specific antigen (PSA) response every 4 weeks in 102 metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone either pre-or postchemotherapy. With a median follow-up was 24.0 months (range: 0.3-54.9), median overall survival (OS) was 20.8 months. High-NLR patients who remained high or who returned to low NLR after 4 and 12 weeks showed significantly worse OS than patients with low baseline NLR. NLR and prostate-specific antigen response to abiraterone was a significant predictor of OS and progression-free survival (PFS) in metastatic castration-resistant prostate cancer patients treated with abiraterone delivered either pre-or postchemotherapy.enginfo:eu-repo/semantics/closedAccessabiraterone acetatecastration resistancehemoglobinneutrophil-to-lymphocyte ratioplatelet-tolymphocyte ratioprognostic factorprostate cancerarticle1513146914790004888716000062-s2.0-85065733602